Why I Invested: A Conversation with MedTech Consultant and Occuity Investor, Chris Gibbs
- Richard Kadri-Langford
- Nov 10, 2025
- 2 min read
Updated: Nov 12, 2025
As Occuity opens its latest crowdfunding round on Republic Europe, we spoke with existing investor Chris Gibbs about what drew him to support the company and how he sees its potential.
“I love the tech. The science nerd in me thinks it is very cool.”
Chris works as a freelance consultant in medical device product development and has previously held roles across R&D in a range of MedTech companies, from start-ups to global businesses. He holds Master’s degrees in Physics and Biomedical Engineering, and has spent much of his career working in regulated, real-world device development.
Chris first came across Occuity through the previous crowdfunding campaign on Seedrs (now Republic Europe). What caught his attention initially was the combination of the team and the technology.
“Occuity has a good combination of a balanced team with the necessary competences and experience, a proprietary platform technology founded on solid scientific principles, and multiple potential market opportunities.”
With that foundation, Chris took a closer look at the underlying science and how Occuity’s approach uses the eye as a non-invasive way to access wider health information.
“I love the tech. The science nerd in me thinks it is very cool.”
He notes that while regulated medical devices can take time to develop and reach the market, Occuity’s progress has been meaningful.
“I know how long it can take to bring a product to market in a regulated industry, and I have been impressed with Occuity’s progress so far, even with the occasional setback.”
Like many investors, Chris has learned more about Oculomics through his involvement with the company. Before investing, he was aware of the basic principle, but not the breadth of potential application.
“I didn’t know much about the area before my investment, but the more I learn, the more I appreciate what it can bring to both diagnostics and disease management across multiple areas.”
Clear communication and keeping our investors and shareholders informed is important to our business and something we pride ourselves on. Developing medical devices is rewarding but not without it's challenges, so we asked Chris about his experience of being a shareholder, and were pleased when Chris highlighted that he values the clarity and tone of communication, summing it up nicely by saying:
“I actually look forward to seeing an email from Dan in my inbox.”
When we asked what most motivates him to stay part of the journey, Chris’s answer, like many of our other investors was very personal.
“I chose a career in medical technology because I believe it allows me to earn a living whilst contributing to society in a small way. Investing in Occuity allows me to support a company that I believe shares this goal.”
Interested to find out more? Watch our new video to discover five reasons why now could be the perfect time to invest in Occuity.
Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.
Comments